Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice

Rodrigues, Maria Augusta Carvalho; Faria, Márcia Cristina da Silva; Santos, Neife Aparecida Guinaim dos; Gobé, Glenda C.; Santos, Antônio Cardozo dos

doi:10.1016/j.cbi.2013.08.015

Cited by 14 publications

(15 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings confirm the renal damage induced by cisplatin and the nephroprotection of CV as we previously demonstrated (Carvalho Rodrigues et al, 2013).…”

Section: A C C E P T E D Accepted Manuscriptsupporting

confidence: 80%

“…BUN and creatinine were measured by using commercially available diagnostic kits (Labtest ®, Lagoa Santa, MG, Brazil) as we previously reported (Carvalho Rodrigues et al, 2013).…”

Section: Renal Functionmentioning

confidence: 99%

“…Additionally, we have demonstrated that CV does not affect the tumor remission and increases the survival rate of tumor-bearing mice treated with cisplatin (Rodrigues et al, 2010, 2011, Carvalho Rodrigues et al, 2013.…”

Section: Introductionmentioning

confidence: 99%

“…Despite the satisfactory results obtained, little is known about the impact of these compounds on the antitumor activity of cisplatin (for revision, see dos . We have demonstrated the protective effect of carvedilol (CV) against the nephrotoxicity induced by cisplatin and have M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT delineated some mechanisms involved in the protection (Rodrigues et al, 2010, 2011, Carvalho Rodrigues et al, 2013.…”

Section: Introductionmentioning

confidence: 99%

“…After 3 days, animals were anesthetized with sodium pentobarbitone (50 mg/kg) and euthanized. Blood, kidneys, and tumors were collected for assays (Carvalho Rodrigues et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of cisplatin

Rodrigues

Santos

Faria

et al. 2016

Chemico-Biological Interactions

Self Cite

View full text Add to dashboard Cite

“…These findings confirm the renal damage induced by cisplatin and the nephroprotection of CV as we previously demonstrated (Carvalho Rodrigues et al, 2013).…”

Section: A C C E P T E D Accepted Manuscriptsupporting

confidence: 80%

“…BUN and creatinine were measured by using commercially available diagnostic kits (Labtest ®, Lagoa Santa, MG, Brazil) as we previously reported (Carvalho Rodrigues et al, 2013).…”

Section: Renal Functionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…After 3 days, animals were anesthetized with sodium pentobarbitone (50 mg/kg) and euthanized. Blood, kidneys, and tumors were collected for assays (Carvalho Rodrigues et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of cisplatin

Rodrigues

Santos

Faria

et al. 2016

Chemico-Biological Interactions

Self Cite

View full text Add to dashboard Cite

The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin

Fernandes

Brito

Baptista

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Cisplatin (CDDP) is used as the first line of treatment for some tumors, but its use may be restricted due to its nephrotoxicity. Carboplatin (CARBO) and oxaliplatin (OXA) are less nephrotoxic alternatives to CDDP. This study has the objective to determine the incidence of acute kidney disease after chemotherapy with CDDP, CARBO, or OXA. Methods A clinical study of a retrospective cohort of patients who underwent treatment with CDDP, CARBO, or OXA from January‐December 2016. Acute kidney Disease (AKD) was defined as elevated serum creatinine (sCR) levels before and up to 3 months after chemotherapy. Morbidities, type of tumor, and treatment data were recorded. Results A total of 212 patients aged 55.5 ± 14.0 years were evaluated. Among the comorbidities, 30% had arterial hypertension (AH) and 11% had diabetes, and 18% were treated with CDDP, 41% with CARBO, and 41% with OXA. There was no difference in sCR levels before and after chemotherapy regardless of the chemotherapy used. The prevalence of eGFRs <60 mL/min after chemotherapy was higher in patients with AH and cardiovascular disease (CVD). The incidence of post‐chemotherapy AKD was 7.0% (n = 13) and the mortality rate was 38.2%. Survival was lower in patients with AKD (P = .012). Conclusions There was a low incidence of AKD among the patients regardless of the chemotherapy used, but the patients with AKD had shorter survival. In addition, the reduction in eGFR after chemotherapy was greater in patients with AH and CVD.

show abstract

Alterations in hematological and biochemical parameters and DNA status in mice bearing Ehrlich ascites carcinoma cells and treated with cisplatin and cyclophosphamide

2020

View full text Add to dashboard Cite

Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice

Cited by 14 publications

References 64 publications

Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of cisplatin

Carvedilol protects the kidneys of tumor-bearing mice without impairing the biodistribution or the genotoxicity of cisplatin

The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin

Alterations in hematological and biochemical parameters and DNA status in mice bearing Ehrlich ascites carcinoma cells and treated with cisplatin and cyclophosphamide

Contact Info

Product

Resources

About